2 ASX growth stocks to buy now and hold for 10 years

These stocks could be destined for very bright futures in the age of AI.

The technology sector has had a volatile start to the year.

Concerns that artificial intelligence could disrupt traditional software companies have led to a broad sell-off across many tech names. Some investors fear artificial intelligence (AI) could lower barriers to entry or even replace certain software platforms entirely.

However, not all software businesses face the same risks. Some companies operate in specialised markets, benefit from powerful ecosystems, or hold critical data that is difficult to replicate.

With that in mind, here are two ASX growth shares that could still deliver strong returns over the next decade.

a man looks down at his phone with a look of happy surprise on his face as though he is thrilled with good news.

Image source: Getty Images

Pro Medicus Ltd (ASX: PME)

One ASX growth share that could be a compelling long-term investment is Pro Medicus.

The healthcare imaging software company has built a strong position in the global radiology workflow market through its Visage platform. The technology allows clinicians to access and analyse extremely large medical imaging files with exceptional speed and reliability.

Medical imaging datasets are becoming larger and more complex as scanners become more advanced. Some modern scans can produce thousands of images or multi-gigabyte files, which creates a growing need for high-performance imaging software.

Pro Medicus has developed streaming technology designed to handle these massive datasets more efficiently than legacy systems. This allows radiologists to access images instantly rather than waiting for them to download, improving productivity and clinical workflows.

The company is also expanding its platform beyond radiology. New modules such as cardiology imaging, workflow software, and digital pathology are extending the product suite and increasing the value delivered to customers.

Importantly, the business still has a long runway for growth. In North America alone, hundreds of millions of imaging exams are performed each year and the company has only penetrated a small portion of the potential market.

While some investors worry that AI could disrupt software companies, Pro Medicus may actually benefit from it. The Visage platform is designed to integrate with AI algorithms and the company is already collaborating with partners and research institutions to develop new AI-powered imaging capabilities.

Given the mission-critical nature of healthcare imaging and the company's technological lead, Pro Medicus could remain a key player in medical imaging workflows for many years.

Xero Ltd (ASX: XRO)

Another ASX growth share that could be worth considering for the next decade is Xero.

The cloud accounting platform provider has built one of the largest ecosystems serving small and medium-sized businesses. Its software sits at the centre of financial operations for millions of customers, handling accounting, payroll, payments, and financial reporting.

One of the key advantages of the platform is the depth of data it holds. By acting as the system of record for financial activity, Xero can provide insights and automation that are deeply integrated into a customer's business operations.

This data foundation may become even more valuable in the age of AI. Rather than replacing accounting platforms, artificial intelligence could expand the capabilities of software like Xero by automating workflows, generating financial insights, and helping businesses make better decisions.

Management believes the rise of AI could significantly expand the addressable market for software platforms over time. Estimates suggest the global SaaS market could grow dramatically as AI unlocks new use cases and productivity tools.

Xero is already embedding AI features across its product suite, including automated bank reconciliation, invoice generation, financial insights, and conversational assistance tools. These features aim to save time for business owners while improving the accuracy of financial management.

With millions of subscribers, a large partner ecosystem, and a growing payments opportunity in markets such as the United States, the platform still has significant room to expand globally.

And if it continues to deepen its ecosystem and leverage AI to enhance its software, Xero could remain a major player in small business financial software for many years to come.

Motley Fool contributor James Mickleboro has positions in Pro Medicus and Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Xero. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Xero. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Growth Shares

Piles of increasing coins alongside an hourglass.
Growth Shares

Why I just invested $1,500 into this top ASX growth share

I’m bullish on the future of this ASX growth share…

Read more »

Woman looking at data on her laptop.
Growth Shares

3 ASX 200 shares I would buy and hold for 10 years

These three businesses have the sort of growth runways I want for a 10-year investment.

Read more »

Coins in ascending order from left to right, with a piggy bank and clock on the sides.
Growth Shares

2 top ASX shares to buy and hold for the next decade

These two investments have incredible long-term outlooks.

Read more »

Rocket going up above mountains, symbolising a record high.
Growth Shares

2 ASX shares tipped to grow 100% or more in the next 12 months

These two stocks could deliver massive returns.

Read more »

Smiling woman pointing at rising graph.
Growth Shares

2 strong Australian stocks to buy now with $9,000

These stocks look like top buys to me right now.

Read more »

Wooden house and golden coins on balancing scale.
Growth Shares

Is the REA Group share price a strong contrarian buy?

Is this a good time to invest in the property portal business?

Read more »

Ascending piles of coins and plants in three jars, with a hand putting a coin in the first jar.
Growth Shares

A rare buying opportunity in 1 of Australia's top shares?

This stock is an ASX leader and it looks like one of Australia’s top shares.

Read more »

Two smiling colleagues looking at a tablet in a data centre.
Growth Shares

Will Goodman shares reach $30 in 2027?

I look at the earnings forecasts to see how realistic a move back to this level could be.

Read more »